Cansino Biologics Inc - Asset Resilience Ratio

Latest as of September 2025: 19.00%

Cansino Biologics Inc (688185) has an Asset Resilience Ratio of 19.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Cansino Biologics Inc for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥1.39 Billion
≈ $203.01 Million USD Cash + Short-term Investments

Total Assets

CN¥7.30 Billion
≈ $1.07 Billion USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Cansino Biologics Inc's Asset Resilience Ratio has changed over time. See 688185 book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Cansino Biologics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 688185 market cap.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥1.39 Billion 19.0%
Total Liquid Assets CN¥1.39 Billion 19.00%

Asset Resilience Insights

  • Good Liquidity Position: Cansino Biologics Inc maintains a healthy 19.00% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Cansino Biologics Inc Industry Peers by Asset Resilience Ratio

Compare Cansino Biologics Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
Drug Manufacturers - Specialty & Generic 0.44%
Emcure Pharmaceuticals Ltd
NSE:EMCURE
Drug Manufacturers - Specialty & Generic 1.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Ningbo Menovo Pharm Co Ltd
SHG:603538
Drug Manufacturers - Specialty & Generic 2.69%
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
Drug Manufacturers - Specialty & Generic 20.24%
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
Drug Manufacturers - Specialty & Generic 0.40%

Annual Asset Resilience Ratio for Cansino Biologics Inc (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Cansino Biologics Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 20.58% CN¥1.64 Billion
≈ $239.84 Million
CN¥7.96 Billion
≈ $1.17 Billion
-1.66pp
2023-12-31 22.25% CN¥2.07 Billion
≈ $303.34 Million
CN¥9.32 Billion
≈ $1.36 Billion
-0.01pp
2022-12-31 22.25% CN¥2.55 Billion
≈ $373.43 Million
CN¥11.47 Billion
≈ $1.68 Billion
+2.66pp
2021-12-31 19.59% CN¥2.33 Billion
≈ $340.37 Million
CN¥11.87 Billion
≈ $1.74 Billion
+9.71pp
2020-12-31 9.88% CN¥666.64 Million
≈ $97.55 Million
CN¥6.75 Billion
≈ $987.46 Million
-21.07pp
2019-12-31 30.95% CN¥552.34 Million
≈ $80.83 Million
CN¥1.78 Billion
≈ $261.13 Million
+13.36pp
2018-12-31 17.59% CN¥140.00 Million
≈ $20.49 Million
CN¥795.88 Million
≈ $116.46 Million
-28.88pp
2017-12-31 46.47% CN¥402.64 Million
≈ $58.92 Million
CN¥866.36 Million
≈ $126.78 Million
+17.66pp
2016-12-31 28.82% CN¥94.00 Million
≈ $13.76 Million
CN¥326.17 Million
≈ $47.73 Million
--
pp = percentage points

About Cansino Biologics Inc

SHG:688185 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.03 Billion
CN¥7.04 Billion CNY
Market Cap Rank
#9007 Global
#2413 in China
Share Price
CN¥61.59
Change (1 day)
+0.13%
52-Week Range
CN¥55.60 - CN¥88.48
All Time High
CN¥773.75
About

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are i… Read more